Study of EVM18001 for hard-to-treat autoimmune diseases
Part of Brain & nervous system, Cancer, Immune system & allergy, Skin clinical trials.
This trial tests a new treatment, EVM18001, for people with lupus, myasthenia gravis, or systemic sclerosis that hasn't improved with standard therapies. It aims to see if this therapy can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have been diagnosed with lupus, myasthenia gravis, or systemic sclerosis for at least 6 months and it must be active despite standard treatments.
- You must have specific blood markers: for lupus, positive ANA, anti-dsDNA, or anti-Smith antibodies; for myasthenia gravis, positive anti-AChR or anti-MuSK antibodies.
- Your bone marrow and major organs (heart, lungs, liver, kidneys) must be working well enough.
- You must not have had certain previous treatments like CAR-T cell therapy or organ transplants.
- You must agree to use effective birth control for 12 months after the last infusion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injection called MTM-H-001 to treat autoimmune diseases where the body's B cells attack itself (like rheumatoid arthritis or lupus). The trial aims to see if this treatment is safe and effective for adults.
This trial tests a new mRNA treatment called HN2301 for people with autoimmune diseases like lupus, scleroderma, or rheumatoid arthritis. It aims to see if the treatment is safe and helps control the disease.
This trial tests a new drug called GR1803 for people with systemic lupus erythematosus (SLE), an autoimmune disease that causes inflammation. It may help reduce disease activity when standard treatments haven't worked well enough.
This early-stage trial tests a new treatment called MTS109 for autoimmune diseases (like lupus, muscle inflammation, scleroderma, vasculitis, or Sjögren's syndrome) that haven't responded well to standard medications. The goal is to see if MTS109 can help control disease that keeps flaring or getting worse despite current treatments.
This trial tests an investigational drug called OL-108 for people with certain autoimmune diseases (lupus, myositis, scleroderma, or vasculitis) that have come back or not responded to standard treatments. The goal is to see if it's safe and if it can help control the disease.
This trial tests an experimental cell therapy (GT719) for people with autoimmune diseases like lupus, inflammatory myositis, or systemic sclerosis that have not responded well to other treatments. It aims to see if this therapy can help control the disease.
Hear when a new System Lupus Erythematosus(SLE) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.